Form 4: Catalyst Pharmaceuticals Director Charles B. O'Keeffe Reports Stock Transaction

Director Charles B. O'Keeffe reports the vesting and delivery of restricted stock units into common stock of Catalyst Pharmaceuticals.

Summary

• On February 14, 2025, Director Charles B. O'Keeffe had 4,000 restricted stock units vest and convert into 4,000 shares of Catalyst Pharmaceuticals common stock.
• This transaction is reported on a Form 4 filing with the SEC.
• Following the transaction, O'Keeffe directly owns 732,470 shares of Catalyst Pharmaceuticals common stock and 208,274 restricted stock units.
• The restricted stock units vested in three equal tranches on February 14, 2023, February 14, 2024, and February 14, 2025.
• The shares of common stock were delivered to O'Keeffe within sixty days of vesting.

Sentiment

Score: 5

Explanation: This is a neutral event, simply reporting a scheduled vesting of stock options. It doesn't inherently indicate positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transaction has a minor dilutive effect on existing shareholders due to the issuance of new shares.
• The vesting of restricted stock units incentivizes the director.

Key Dates